Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2015

View Archived Issues

High-fat meal alters the pharmacokinetic profile of atorvastatin/metformin FDC

Galapagos introduces a new branimycin derivative DNA polymerase III inhibitor

Prolastin-C designated an orphan drug in U.S. for treating type 1 diabetes

Ruthigen and Pulmatrix to merge

GSK plans first-in-human study of GSK-2330811 for inflammatory and fibrotic diseases

Lakewood-Amedex and University of Jyvaskyla to test bisphosphocins for Borrelia burgdorferi

Galapagos regains rights to GLPG-1690 and announces end of alliance with Janssen

ADRA2A polymorphism associated with breast cancer severity

New genetic biomarkers associated with Hirschprung disease

Egalet earns milestone payment triggered by advancement of Shionogi's S-718632

Qiagen acquires CTC technology, enters companion diagnostic agreement with Tokai

Symbiomix's antibacterial drug candidate is safe and well tolerated

Actavis completes acquisition of Allergan

GlaxoSmithKline initiates phase III program of retosiban in preterm labor

Fujifilm reports novel ATM kinase inhibitors

Roche presents novel PAMs of muscarinic M1 receptor

Senju Pharmaceutical presents miRNA-203 inhibitor

GliaCure receives grant for phase Ib Alzheimer's trial

Neurotrope reports final results from phase IIa safety study of bryostatin 1 for Alzheimer's

Merck & Co. patents adenosine A2A receptor antagonists

Nektar Therapeutics discloses top-line results from phase III trial of NKTR-102 in breast cancer

Phase III study of Imbruvica combination meets primary endpoint

Celldex Therapeutics and Roche to evaluate the combination of varlilumab and MPDL-3280A

Iclusig now has U.S. and E.U. orphan drug status for gastrointestinal stromal tumors

Lundbeck initiates phase III study of clobazam in children with Dravet syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...